Successful moxifloxacin prophylaxis against experimental streptococcal aortic valve endocarditis

Journal of Antimicrobial Chemotherapy

Volumn 56, Issue 6, 2005, Pages 1160-1162

  Sakka, Vissaria ^a   Galani, Lambrini ^a   Pefanis, Angelos ^a   Iliopoulos, Dimitrios ^a   Athanasopoulos, George ^a   Donta, Ismini ^a   Giamarellou, Helen ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

Ampicillin; Fluoroquinolones; Rabbits; Streptococcus oralis

Indexed keywords

AMPICILLIN; MOXIFLOXACIN; POLYETHYLENE; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA VALVE DISEASE; ARTICLE; BACTERIAL ENDOCARDITIS; BACTERIAL GROWTH; CATHETER; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; INFECTION PREVENTION; INOCULATION; NONHUMAN; OUTCOMES RESEARCH; RABBIT; STATISTICAL SIGNIFICANCE; STREPTOCOCCUS INFECTION; STREPTOCOCCUS ORALIS;

AMPICILLIN; ANIMALS; ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; AORTIC VALVE; AZA COMPOUNDS; COLONY COUNT, MICROBIAL; DISEASE MODELS, ANIMAL; ENDOCARDITIS, BACTERIAL; FEMALE; HEART VALVE DISEASES; QUINOLINES; RABBITS; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS ORALIS;

EID: 29444445065     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dki363     Document Type: Article

References (10)

1. Dajani AS, Taubert KA, Wilson W et al. Prevention of bacterial endocarditis: Recommendations by the American Heart Association. Clin Infect Dis 1997; 25: 1448-58.
2. McWhinney PH, Patel S, Whiley RA et al. Activities of potential therapeutic and prophylactic antibiotics against blood culture isolates of viridans group streptococci from neutropenic patients receiving ciprofloxacin. Antimicrob Agents Chemother 1993; 37: 2943-5.
3. Teng LJ, Hsueh PR, Chen YC et al. Antimicrobial susceptibility of viridans group streptococci in Taiwan with an emphasis on the high rates of resistance to penicillin and macrolides in Streptococcus oralis. J Antimicrob Chemother 1998; 41: 621-7.
4. Keating GM, Scott LG. Moxifloxacin: A review of its use in the management of bacterial infections. Drugs 2004; 64: 2347-77.
5. Perlman BB, Freedman LR. Experimental endocarditis II: Staphylococcal infection of the aortic valve following placement of a polyethylene catheter in the left side of the heart. Yale J Biol Med 1971; 44: 206-21.
6. Bayer AS, Tu J. Chemoprophylactic efficacy against experimental endocarditis caused by β-lactamase-producing, aminoglycoside-resistant enterococci is associated with prolonged serum inhibitory activity. Antimicrob Agents Chemother 1990; 34: 1068-74.
7. Voorn GP, Thompson J, Goessens WHF et al. Efficacy of ciprofloxacin in treatment and prophylaxis of experimental Staphylococcus aureus endocarditis caused by a cloxacillin-tolerant strain and its non-tolerant variant. J Antimicrob Chemother 1994; 33: 785-94.
8. Katsarolis I, Pefanis A, Iliopoulos D et al. Successful trovafloxacin prophylaxis against experimental streptococcal aortic valve endocarditis. Antimicrob Agents Chemother 2000; 44: 2564-6.
9. Pefanis A, Perdicaris G, Delis D et al. Sparfloxacin in the prophylaxis of experimental endocarditis due to Gram-positive cocci. In: Program and Abstracts of the Thirty-sixth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 1996. Abstract B65, p. 33. American Society for Microbiology, Washington, DC, USA.
10. Moreillon P. Endocarditis prophylaxis revisited: Experimental evidence of efficacy and new Swiss recommendations. Swiss Working Group for Endocarditis Prophylaxis. Schweiz Med Wochenschr 2000; 130: 1013-26.